Pharmacoscopy-guided Clinical Standard-of-care in r/r AML

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
With an overall survival of below 12 months, the outcome of relapsed/refractory AML (RR AML) is poor, making it a critical challenge to identify effective therapies at this stage. The RAPID-01 trial aims to show for the first time in a randomized and controlled clinical trial that Pharmacoscopy (PCY), a functional precision medicine platform, helps improve clinical standard-of-care treatment selection for patients suffering from relapsed/refractory AML.
Epistemonikos ID: 332e7cab8cac74c69cb1eed39e0b49ffdd67da17
First added on: May 15, 2024